University of Pennsylvania, Scientific Director of Clinical Research, Dept of Radiation Oncology
Radiation Oncology
Dr. John P. Plastaras, MD
|
|
Give Review
Dr. John P. Plastaras is an expert in the field of Radiation Oncology. He went to Vanderbilt University School of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Dr. John P. Plastaras has written publications. He has 64 publications published with PubMed. The lastest publication is: 'Determination of malondialdehyde-induced DNA damage in human tissues using an immunoslot blot assay.' He accepts Medicare.
Publications
- Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
- A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer.
- Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer.
- Proton pencil beam scanning for mediastinal lymphoma: the impact of interplay between target motion and beam scanning.
- Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy.
- Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons.
- Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer.
- In regard to morris.
- The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
- Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia.
- The impact of stool and gas volume on intrafraction prostate motion in patients undergoing radiotherapy with daily endorectal balloon.
- Clinical utility of integrated positron emission tomography/computed tomography imaging in the clinical management and radiation treatment planning of locally advanced...
- Can radiotherapy be omitted in patients with localized hodgkin lymphoma?
- Proton therapy in adjuvant treatment of gastric cancer: Planning comparison with advanced x-ray therapy and feasibility report.
- Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET.
- ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
- Stage Migration in Planning PET/CT Scans in Patients Due to Receive Radiotherapy for Non-Small-Cell Lung Cancer.
- Diffusely metastatic digital papillary adenocarcinoma 11 years after initial presentation treated with palliative chemotherapy and radiotherapy.
- Radiation Oncology: a Primer for Medical Students.
- Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced ...
- The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer.
- Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clini...
- A clinically feasible method for the detection of potential collision in proton therapy.
- Commentary: navigating a data desert: cochrane leaves the question of intracystic bleomycin unanswered in craniopharyngioma.
- Dosimetric consequences of pancreatic tumor motion when predetermined treatment margins are employed during intensity-modulated radiation therapy.
- The Case for Combined-Modality Therapy for Limited-Stage Hodgkin's Disease.
- An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.
- A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management.
- Feasibility of Electromagnetic Transponder Use to Monitor Inter- and Intrafractional Motion in Locally Advanced Pancreatic Cancer Patients.
- Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon.
- Daily isocenter correction with electromagnetic-based localization improves target coverage and rectal sparing during prostate radiotherapy.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
- Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?
- A one, two punch for liver cancer: anti-angiogenesis with a death receptor agonist.
- Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis.
- Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.
- Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.
- Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.
- Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
- Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
- Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
- Paget's disease of the nipple as local recurrence after breast-conservation treatment for early-stage breast cancer.
- Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment.
- Effects of DNA structure on oxopropenylation by the endogenous mutagens malondialdehyde and base propenal.
- Reaction of malondialdehyde-DNA adducts with hydrazines-development of a facile assay for quantification of malondialdehyde equivalents in DNA.
- Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers.
- Predicting Outcomes in Locally-Advanced Rectal Cancer Using Pretreatment FDG-PET Imaging.
- Abdominal and pancreatic motion correlation using 4D CT, 4D transponders, and a gating belt.
- Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
- TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.
- Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients.
- Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells.
- Endogenous DNA damage and mutation.
- Reactivity and mutagenicity of endogenous DNA oxopropenylating agents: base propenals, malondialdehyde, and N(epsilon)-oxopropenyllysine.
- Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde.
- A sensitive immunoslot-blot assay for detection of malondialdehyde-deoxyguanosine in human DNA.
- Determination of malondialdehyde-induced DNA damage in human tissues using an immunoslot blot assay.
- Comparison of DNA adduct levels associated with oxidative stress in human pancreas.
- Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal.
- Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products...
- Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?
- The impact of comorbidities on outcomes for elderly women treated with breast-conservation treatment for early-stage breast cancer.
- Measurement of a malondialdehyde-DNA adduct.
Schools
Vanderbilt University School Of Medicine
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Pennsylvania Health System -
Memorial Sloan-Kettering Cancer Center -
Vanderbilt University School of Medicine
Hospital
-
Penn Presbyterian Medical Center -
Hospital of the University of Pennsylvania -
Philadelphia Veterans Affairs Medical Center -
Pennsylvania Hospital
Drug Facts
| NPI NUMBER | 1720144512 | |
| NPPES Provider LastName | PLASTARAS | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 191044306 | |
| NPPES Provider State | PA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 36.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720144512 |
| Last Name Of The Provider | PLASTARAS |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. David M. Guttmann, MD |
|
|
Dr. Mark A. Hallman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven J. Feigenberg, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lynn Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wilhelm Lubbe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard K. Valicenti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark V. Mishra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren M. Hertan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric M. Horwitz, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nathan D. Jones, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith A. Cengel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry Quon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|